BRIEF-Pediapharm receives FDA supplement approval regarding Naproxen suspension

Wed May 11, 2016 8:42am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

May 11 (Reuters) - Pediapharm Inc :

* Approval triggered second and final payment of us$2 million in cash

* Pediapharm receives fda supplement approval regarding naproxen suspension in the us, receives additional us$2 million from atnahs pharma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)